For the new clinical trial, led by the University of Cambridge, an existing drug, deferiprone, will be given to 40 patients, who will take the medicine for a year. Deferiprone is already used to ...

Deferiprone is a chelating agent that binds with ferric ions (iron III) to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. <8yrs: not established.